Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 15:10:587981.
doi: 10.3389/fonc.2020.587981. eCollection 2020.

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients

Samantha S Sigurdson  1 , Francisco E Vera-Badillo  2 , Fabio Ynoe de Moraes  1
Affiliations

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients

Samantha S Sigurdson et al. Front Oncol. .
No abstract available

Keywords: cost-effective; hormone therapy; metastatic prostate cancer (mPCa); radiotherapy; systemic therapy.

PubMed Disclaimer

References

    1. Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol (2019) 76(1):115–24. 10.1016/j.eururo.2019.02.003 - DOI - PMC - PubMed
    1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med (2015) 373(8):737–46. 10.1056/NEJMoa1503747 - DOI - PMC - PubMed
    1. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (2016) 387(10024):1163–77. 10.1016/S0140-6736(15)01037-5 - DOI - PMC - PubMed
    1. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med (2017) 377(4):338–51. 10.1056/NEJMoa1702900 - DOI - PMC - PubMed
    1. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol (2019) 20(5):686–700. 10.1016/S1470-2045(19)30082-8 - DOI - PubMed

LinkOut - more resources